Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Esperite (voorheen Cryo Save) Terug naar discussie overzicht

Esperite 2016

3.912 Posts
Pagina: «« 1 ... 185 186 187 188 189 ... 196 »» | Laatste | Omlaag ↓
  5. forum rang 6 sportliefhebber 19 december 2016 18:29

    • sportliefhebber

      Lid sinds: 22 nov 2004

      Laatste bezoek: 12 apr 2025

    • Aanbevelingen

      Ontvangen: 1515

      Gegeven: 2266

    •    Aantal posts: 6.475

    quote:

    ch@rter schreef op 19 december 2016 16:42:

    [...]

    Geef het nou gewoon op diegy .. voor die paar lowsy % op dit soort volume ..

    Wie zou in hemelsnaam de hut willen hebben.

    Emissie, en andere ophaalronde ligt onder de kerstboom te wachten om uitgepakt te worden. Kortom het is het stutten vd koers.
    Tja....valt blijkbaar tegen, dat de koers nog niet op 1,10 of lager staat, zoals je eergisteren aangaf. 1,40 of 1,10 is toch een aardig verschil...
    Er zijn genoeg belangstellenden, dus geef die (des) interesse in Esperite nou maar op.
  13. [verwijderd] 19 december 2016 19:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ||| schreef op 19 december 2016 16:50:

    [...]

    Met de potentie die esperite bezit...Ik vermoed best veel bedrijven...

    Nou, ik zou zeggen som eens wat bedrijven op ..
  14. [verwijderd] 19 december 2016 19:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    sportfanaat schreef op 19 december 2016 18:29:

    [...]
    Tja....valt blijkbaar tegen, dat de koers nog niet op 1,10 of lager staat, zoals je eergisteren aangaf. 1,40 of 1,10 is toch een aardig verschil...
    Er zijn genoeg belangstellenden, dus geef die (des) interesse in Esperite nou maar op.

    Welnee man, veel te leuk hier.
    Ik wacht de emissie nog gewoon even af.
  15. machmit 19 december 2016 19:27

    • machmit

      Lid sinds: 04 aug 2011

      Laatste bezoek: 16 feb 2023

    • Aanbevelingen

      Ontvangen: 167

      Gegeven: 76

    •    Aantal posts: 1.366

    quote:

    DeZwarteRidder schreef op 19 december 2016 19:06:

    [...]
    Valse info...!!
    Nu je mijn aanbod negeert, zal ik als tegenprestatie even je geheugen opfrissen:

    DeZwarteRidder schreef op 6 dec 2016 om 13:46:

    [...]
    Dat was een NEP-stijging door een Franse shuffle, dankzij een NEP-bericht.
    Dat gebeurt niet meer nu bekend is dat ESP blut is.

    Leg me eens uit hoe jij je zo kon vergissen, want nu is de stand 1,40.
  17. forum rang 6 sportliefhebber 19 december 2016 19:31

    • sportliefhebber

      Lid sinds: 22 nov 2004

      Laatste bezoek: 12 apr 2025

    • Aanbevelingen

      Ontvangen: 1515

      Gegeven: 2266

    •    Aantal posts: 6.475

    quote:

    ch@rter schreef op 19 december 2016 19:22:

    [...]

    Welnee man, veel te leuk hier.
    Ik wacht de emissie nog gewoon even af.
    Dat bedoel ik.....veel interesse.
  18. [verwijderd] 19 december 2016 19:33

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ch@rter schreef op 19 december 2016 19:20:

    [...]

    Nou, ik zou zeggen som eens wat bedrijven op ..
    Die lijst kan behoorlijk oplopen...maargoed.

    Even een paar voorde hand liggende:

    3 Companies Investing In Stem Cell Research

    Craig Adeyanju September 14, 2014

    Against all odds, stem cell therapies are now getting significant attention from the pharmaceutical industry.

    This means that Big Pharma is now seeing that the upside potential of stem cell therapies outweighs the downsides.

    While certain things about the stem cell initiative remain controversial –- notably embryonic stem cells –- some interesting events have occurred recently. These events will, perhaps, encourage more companies to consider investing in stem cell research.

    For example, a heart attack victim in London had an experimental surgery that involved the injection of stem cells from his hip into his heart to encourage his heart to repair itself.

    The experiment has been successful so far with 37 percent of the victim’s heart muscle now functioning, up from 21 percent after the heart attack.

    Researchers behind this new technique hope that it will increase survival rate from heart attacks by a quarter. Since the Centers for Disease Control and Prevention has said that about 600,000 people die of heart attack in the U.S. every year, this would mean that 150,000 more people could still be alive every year in the U.S.

    In light of this development, here are three companies that are investing in stem cell research.

    Related: Why Investors Should Closely Watch Celgene

    Novartis (NYSE: NVS)
    This health care giant has been involved in helping stem cell therapies for about 30 years now, having developed ciclosporin 31 years ago.

    Novartis recently broadened its position in the stem cell space by agreeing to take a 15-percent stake in Gamida Cell, an Israeli developer of stem cell therapies. The terms of the agreement has Novartis investing $35 million in Gamida immediately for the stake.

    The agreement also gives Novartis the option -– which expires in the first half of 2016 –- to fully acquire the company, provided certain milestones are achieved regarding the development of NiCord. In this case, the acquisition could come up as early as 2015.

    Norvatis announced on September 6 that it partnered with Regenerex to gain access to Regenerex’s stem cell technology, which would help the company develop groundbreaking therapies for underserved diseases.

    Johnson & Johnson Company (NYSE: JNJ)
    Johnson & Johson kicked off the year by betting $12.5 million on the Capricor Therapeutics (OTC: CAPR) cell therapy program for cardiovascular applications –- notably CAP-1002 –- through its subsidiary, Janssen Pharmaceuticals, Inc.

    Through Janssen Pharmaceuticals, J&J invested in ViaCyte’s VC-01 combination product being developed for type 1 diabetes. This came after the ViaCyte obtained approval from the FDA to start a clinical trial of the candidate.

    J&J is to provide ViaCyte with $20 million.

    Celgene Corporation (NASDAQ: CELG)
    Celgene is perhaps the boldest big pharmaceutical company out there at the moment, in terms of commitment in stem cell research.

    A previous article on Benzinga discussed how a robust drug portfolio qualifies the company to be on investors’ watch list. Its commitment in stem cell adds another reason to watch this company.

    Late last year, Celgene entered into an agreement with OncoMed (NASDAQ: OMED) for the development of six anti-cancer stem cell antibodies and certain small molecule stem cell drugs based on OncoMed’s study. Celgene committed $155 million in upfront cash to the project.

    Under certain conditions in the agreement, the deal could increase to $3.3 billion. The company also entered into an agreement with Human Longevity Inc recently to license, develop and co-promote Celgene’s placental cell population, PSC-100. This collaboration also goes to show just how serious Celgene is in holding a significant position in the stem cell space.

    Place your bets... :-)
  19. [verwijderd] 19 december 2016 19:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    HOME » EVOTEC, CELGENE INK DRUG DEVELOPMENT DEAL FOR STEM CELL TREATMENTS FOR NEURODEGENERATIVE DISEASES
    Evotec, Celgene ink drug development deal for stem cell treatments for neurodegenerative diseases

    DECEMBER 16, 2016 BY SARAH FAULKNER

    Evotec, Celgene ink drug development deal for stem cell treatements for neurodegenerative diseasesEvotec (ETR:EVT) said today that it inked a 5-year drug discovery and development deal with Celgene (NSDQ:CELG) to identify stem cell therapies for a range of neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease.

    According to the agreement, Hamburg, Germany-based Evotec will receive an upfront payment of $45 million and Celgene will hold exclusive worldwide licensing rights to Evotec programs developed from the company’s compound library. Evotec could also receive up to $250 million in milestones and low double-digit royalties on in-licensed programs.

    Best actueel ook...

3.912 Posts
Pagina: «« 1 ... 185 186 187 188 189 ... 196 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.161
AB InBev 2 5.544
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.503
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.931
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.892
Aedifica 3 927
Aegon 3.258 323.212
AFC Ajax 538 7.093
Affimed NV 2 6.306
ageas 5.844 109.909
Agfa-Gevaert 14 2.074
Ahold 3.538 74.361
Air France - KLM 1.025 35.329
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.068
Alfen 16 25.502
Allfunds Group 4 1.525
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.250
AMG 972 134.754
AMS 3 73
Amsterdam Commodities 305 6.754
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.106
Apollo Alternative Assets 1 17
Apple 5 387
Arcadis 252 8.808
Arcelor Mittal 2.035 321.095
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.379
Aroundtown SA 1 221
Arrowhead Research 5 9.758
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.697
ASML 1.767 112.202
ASR Nederland 21 4.522
ATAI Life Sciences 1 7
Atenor Group 1 523
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.344
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.463

Macro & Bedrijfsagenda

  1. 14 april

    1. Theon jaarcijfers
    2. Kendrion jaarvergadering
    3. Internationale handel februari (NL)
    4. Aalberts ex-dividend
    5. Goldman Sachs Q1-cijfers (VS)
    6. OPEC maandrapport (Oos)

  2. 15 april

    1. Ctac jaarvergadering
    2. PostNL jaarvergadering
    3. TomTom Q1-cijfers
    4. Beiersdorf Q1-cijfers (Dld)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda